KCAS Bioanalytical and Biomarker Services, a laboratory services focused contract research organization (CRO), is pleased to announce the expansion of their Biopharmaceutical Services team. Dr. Jeff Hester, Ph.D., joins KCAS to lead the buildup and growth of the organization’s Cell and Gene Therapy Services.
Dr. Hester’s role will be to provide vision, leadership, and scientific expertise to advance KCAS’ investments into this rapidly growing area of drug development. He brings extensive experience with leading scientific service organizations and has decades of experience supporting BioPharma clients’ development programs. Dr. Hester’s expertise in advanced technical platforms, scientific presentations, and CRO organizational development capabilities will bring more value to the KCAS’ clients as we continue to invest in growth, technical platforms, and scientific and leadership talent.
"My role will be expanding upon KCAS’ innovative drug development services and solutions. I am delighted to focus on growing the organization’s current cell and gene therapy services into a world class offering, servicing the biotech and pharma industries. My background and experience position me to advance cell and gene therapy and CAR-T cells programs and are natural addition to KCAS’ already strong biopharmaceutical service line offerings," stated Dr. Hester.
"Dr. Hester joining our team is a real exciting development. Jeff’s leadership at previous CROs is well regarded and we look forward to the opportunity to support Jeff and his team as we continue to invest in the business. He brings with him a very strong background in cell and gene therapy as well as vaccine development. Combined with strong technical background in Biopharmaceutical drug development and operational leadership, KCAS is now positioned to expand our service offerings in these areas with Dr. Hester’s leadership. KCAS’s recent announcement regarding acquisition by Vitruvian Partners positions us to continue investment to support our growth trajectory at KCAS," stated John Bucksath, CEO.
Dr. Hester joins KCAS from Eurofins ViraCor, Inc based in Lee’s Summit, Missouri where he was the Vice President of Research and Development. There he was a member of the executive team with P&L responsibility for BioPharma custom bioassays and clinical diagnostics development programs. Dr. Hester earned his B.S. and Ph.D. in Chemistry from the University of Cincinnati, Ohio.
KCAS Bioanalytical and Biomarker Services, an Integris BioServices, LLC Company, is a rapidly growing company that provides comprehensive GLP / GCP compliant development services from early discovery support through product registration and beyond. One of only a select few CROs offering both large and small molecule development with extensive capabilities and expertise, KCAS provides a truly differentiated approach to its clients who are looking for both scientific expertise and excellent customer service. KCAS’ headquarters is in Shawnee, Kansas – the Kansas City metro area and employs more than 180 employees. Visit www.kcasbio.com for more information about the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005981/en/